The article is a response to a letter from Drs de Grooth and Parienti regarding a trial-level surrogacy analysis. The authors explain that they were unable to reanalyze their study to compare results with the letter's suggestions due to a lack of data. However, they highlight the beneficial effects of a specific treatment in lowering RNA levels and reducing hospitalization/death. The authors also discuss the value of meta-regression analysis in evaluating treatment effectiveness and suggest the need for comprehensive trial identification and access to participant-level data in future pandemics. [Extracted from the article]